A novel defensin antimicrobial peptide from mussels was successfully produced in yeast with correct folding, showing broad-spectrum antibacterial activity with low toxicity to mammalian cells.
8,849.9 Da — structure confirmedThe recombinant mussel defensin was produced with the exact predicted molecular weight and correct disulfide bond formation in yeast, overcoming a major production challenge for complex antimicrobial peptides.
What the researchers found
Recombinant myticofensin-B1 (65 amino acids, 6 conserved cysteine residues forming 3 disulfide bonds) was successfully expressed in Pichia pastoris with a confirmed molecular weight of 8,849.9 Da matching the theoretical prediction. LC-MS/MS confirmed structural fidelity.
The recombinant peptide demonstrated broad-spectrum antimicrobial activity with stronger inhibition against Gram-negative bacteria. Scanning electron microscopy revealed the peptide affected different bacterial species through different physical mechanisms. Importantly, it showed very low hemolytic activity against sheep red blood cells (indicating safety for blood cells) and weak cytotoxicity against human A549 lung cancer cells.
Why it matters
Antimicrobial resistance is a growing global crisis, and natural antimicrobial peptides from marine organisms represent a vast untapped reservoir of potential new antibiotics. However, producing these complex peptides at scale has been a major bottleneck — bacterial expression systems often fail because the peptides' positive charges and disulfide bonds are toxic or incompatible. This study solves that problem for mussel defensins by establishing a yeast-based production platform, opening the door to large-scale production and further drug development.
How the study worked
The gene encoding mature myticofensin-B1 was codon-optimized for yeast expression, cloned into a pPICZαA vector, and expressed in Pichia pastoris strain GS115. The recombinant peptide was characterized by liquid chromatography-tandem mass spectrometry (LC-MS/MS) for structural verification. Antimicrobial activity was tested against multiple bacterial species. The peptide's effects on bacterial cells were visualized by scanning electron microscopy. Safety was assessed through hemolysis assays (sheep red blood cells) and cytotoxicity testing (human A549 lung cancer cells).
What this study cannot tell us
The study focuses on production methodology and initial characterization rather than comprehensive therapeutic evaluation. Antimicrobial activity was demonstrated in vitro but not in animal infection models. The specific bacteria tested and minimum inhibitory concentrations are not detailed in the abstract. The primary application highlighted is aquaculture rather than human medicine. Long-term stability of the recombinant peptide and its behavior under physiological conditions are not addressed.
How to read the evidence
This is a biotechnology methods paper demonstrating successful heterologous production and initial characterization of a novel antimicrobial peptide. The structural verification by LC-MS/MS is rigorous. The antimicrobial and safety data are preliminary — broader pathogen panels, in vivo testing, and pharmacological characterization would be needed for therapeutic development.
When this study was published
Published in 2025, this study represents current advances in antimicrobial peptide production technology. The field is rapidly progressing toward scalable production of complex marine peptides.
The bigger picture
Marine organisms are increasingly recognized as rich sources of novel antimicrobial peptides. Mussels, which thrive in pathogen-rich aquatic environments, have evolved particularly potent immune peptides. Defensins — a conserved antimicrobial peptide family found across mollusks, insects, plants, and mammals — are especially promising because they kill bacteria through membrane disruption, making resistance difficult to develop. Establishing scalable production in yeast is a critical step toward clinical development of these natural antibiotics.
Questions still open
- Can the yeast expression system be scaled up to produce commercially viable quantities of myticofensin-B1?
- Would myticofensin-B1 be effective against antibiotic-resistant human pathogens like MRSA or multi-drug resistant Gram-negatives?
- Could the low cytotoxicity against mammalian cells support future development as a human therapeutic antibiotic?
Common questions
Why is it so hard to produce antimicrobial peptides from mussels in the lab?
Could mussel peptides become new antibiotics for humans?
Read the original research
Recombinant expression of a novel Mytilus defensin in Pichia pastoris.
Sheng wu gong cheng xue bao = Chinese journal of biotechnology, 42(2), 852-864
Citation
Xiao, Wenhui; Song, Fang; Chen, Chuanyue; Huang, Fangfang; Yang, Qiaomei; Zhang, Xiaolin; Liao, Zhi. (2025). Recombinant expression of a novel Mytilus defensin in Pichia pastoris.. Sheng wu gong cheng xue bao = Chinese journal of biotechnology, 42(2), 852-864. https://doi.org/10.13345/j.cjb.250418